Managing Oral Lesions with Omega-3: Meta-Analysis
A recent meta-analysis has revealed that omega-3 polyunsaturated fatty acids serve as a transformative intervention for painful oral conditions, significantly reducing pain scores and enhancing mucosal healing across various clinical trials, as published in the Journal of the Indian Academy of Oral Medicine and Radiology in March 2026.
Oral mucosal lesions, which are driven by inflammatory mediators like arachidonic acid derivatives, often require treatments like steroids that may cause significant adverse effects, yet despite the known benefits of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in systemic conditions like rheumatoid arthritis, a clear consensus for oral health was previously lacking. Addressing this clinical gap, Turaga Amani and Sreedevi Dharman from the Saveetha Dental College and Hospitals in Chennai, India, conducted the first comprehensive systematic review to evaluate the therapeutic potential of these essential lipids in managing oral inflammatory lesions.
Therefore, the systematic review analyzed seven randomized controlled trials involving 322 patients with oral mucositis, oral submucous fibrosis (OSMF), or recurrent aphthous stomatitis (RAS). Interventions included 1000 mg oral omega-3 capsules (thrice daily) or topical nanoemulgels. Clinical evaluations prioritized Visual Analog Scale (VAS) pain reduction, alongside functional outcomes like mouth opening and quality of life
Key Clinical Findings of the review Includes:
• Significant Pain Reduction: Clinicians found that the use of omega-3 PUFAs led to a consistent and notable reduction in pain intensity across multiple lesion types as measured by the Visual Analog Scale.
• Improved Functional Outcomes: For patients suffering from oral submucous fibrosis, the review indicated significant improvements in tongue protrusion, cheek flexibility, and mouth opening, which are critical for restoring daily function.
• Reduced Mucositis Severity: The review noted that patients undergoing radiotherapy or chemotherapy experienced lower World Health Organization (WHO) mucositis grades when supplemented with omega-3 formulations compared to control groups.
• Faster Ulcer Healing: In the management of recurrent aphthous stomatitis, omega-3 treatment showed a promising trend toward reduced ulcer size and shorter healing durations, with some studies favoring it over placebo.
• Enhanced Quality of Life: Standardized questionnaires, such as the Oral Health Impact Profile-14, demonstrated that participants experienced a better overall quality of life and reduced burning sensations following treatment.
The results suggest that omega-3 PUFAs are a potent standalone or supportive therapy for oral health, as evidenced by pooled data from recurrent aphthous stomatitis patients showing a pain reduction standardized mean difference of -3.31 and a healing duration improvement of 3.34.
Thus, integrating omega-3 fatty acid supplementation into routine clinical practice may offer a safe, cost-effective, and well-tolerated method to improve functional recovery and patient comfort in chronic oral mucosal diseases.
While the initial findings are highly encouraging, the researchers noted that the review was limited by small sample sizes and moderate heterogeneity, suggesting that larger, standardized trials are necessary to firmly establish these fatty acids within evidence-based clinical protocols.
Reference
Amani T, Dharman S. Effect of omega‑3 polyunsaturated fatty acids in management of oral mucosal lesions: A systematic review with a meta-analysis focused on recurrent aphthous stomatitis. J Indian Acad Oral Med Radiol 2026;38:11-8.
